Q compare to CXRI thought the quater was pretty good, at least no nasty surprise like CXR Q2, had cut all my losses in CXR as soon as I got off the Q2 Conference call when market opened. Got so nervous to the point that I had also cut down my MSL holdings on Friday expecting earning dissappoint given potential increased competitive pressure in the generic drug space. I am pleased to see the MSL is able to stay with its guidance I am going to increase my holding given the results.